Focus Investment Banking

APRIL 14, 2024

It’s no surprise that bakery is one of the food industry’s most dependable performers. As a staple food, it’s insulated from fluctuations in household incomes and business cycles compared to the broader food and beverage industry. The bakery category is also incredibly resilient. The $75 billion U.S.

M&A 52

M&A Food Private Equity Manufacturing 52

Focus Investment Banking

JANUARY 3, 2024

FAT Brands bought Smokey Bones for $30 million, which adds the first barbeque brand to FAT’s growing portfolio. Cava opened the IPO window and showed that a good company can go public in any market. Subway sold to Roark Capital for $9.6 The partnership enables Smokey Bones to grow via FAT’s aggressive franchising strategy as well.

Acquisitions 52

Acquisitions M&A Portfolio Valuation 52

Growth Business

JUNE 1, 2023

1 – Do your research and take a portfolio approach to your investments As with any other financial endeavour, angel investing comes with a certain degree of risk. Becoming an angel investor can be an incredibly rewarding experience and, over the years, I’ve enjoyed meeting the entrepreneurs behind potentially ground-breaking innovations.

Investors 52

Investors Investment Business Capital 52

Growth Business

SEPTEMBER 13, 2023

of investments each year: 20+ Previous companies invested in: OculusVR, Flexport, Archax, SciFi Foods, Universal Quantum No. It was an early investor in Babylon Health, Darktrace and Deliveroo, and its portfolio companies have grown to an aggregate value of over $7bn. of successul exits: 8 Website: www.7pc.vc Contact: www.7pc.vc/contact

Capital 52

Capital Business Funds Investment 52

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years. The theme is not entirely new, however.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64